Sunitinib in metastatic renal cell carcimoma: A single-center experience

Krishna, Vidya; Noronha, Vanita; Prabhash, Kumar; Joshi, Amit; Patil, Vijay; Bhosale, Bharat; Thippeswamy, Ravi; Menon, Hari; Gupta, Sudeep; Banavali, Shripad; Bakshi, Ganesh; Tangaonkar, H B

doi:10.4103/0019-509x.118725

Cited by 8 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median PFS was 10.2 months in our study, 11.4 months in Krishna et al .,[13] 9.3 months in Yuasa et al .,[13] 8.2 months in Kim et al .,[15] and 11.0 months in Motzer et al . [16]…”

Section: Discussionsupporting

confidence: 48%

“…It was less when compared with 80.95% in Yuasa et al . [13] In our study, 68.42% of patients presented earlier with metastatic disease, i.e., <1 year when compared to 47.61% in Yuasa et al . study.…”

Section: Discussioncontrasting

confidence: 46%

“…[13] and 90.2% in Kim et al . [15] The clinical efficacy rate (CR + PR + SD) was 86% in our study when it was 81% in Yuasa et al .…”

Section: Discussionmentioning

confidence: 99%

“…[15] The clinical efficacy rate (CR + PR + SD) was 86% in our study when it was 81% in Yuasa et al . [13] and 76% in Krishna et al . [13]…”

Section: Discussionmentioning

confidence: 99%

“…The median OS in our patients was 28.2 months when compared to 22.6 months in Krishna et al .,[14] 32.2 months in Yuasa et al . [13] and 23.1 months in Kim et al . [15]…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world

Kumar

Gundeti

Krishnamani

et al. 2016

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction:Renal cell carcinoma (RCC) is the most common cancer of the kidney accounting for 85% of renal tumors. Metastatic RCC (mRCC) had a poor prognosis and with the introduction of tyrosine-kinase inhibitors, such as sunitinib, pazopanib the outcomes improved. There is only one study reported from India on the use of sunitinib in mRCC. We present our analysis of mRCC and use of sunitinib at our institute over 5 years.Materials and Methods:All patients with mRCC receiving sunitinib were analyzed with respect to patient characteristics, response, toxicity, and outcomes.Results:A total of 108 patients were seen during the study period. The male to female ratio was 9.8:1. The median age of patients at presentation was 58 years (range: 15–80 years). Of the 108 patients, 68.51% had metastatic disease at initial presentation. The most common sites of metastases were lung followed by bone. Of the 97 patients eligible for sunitinib, only 76 received at least one cycle of sunitinib, out of which only 48 received further cycles (range: 2–36). The median progression-free survival (PFS) and overall survival (OS) in our patients were 10.2 and 28.2 months, respectively. The most common adverse effect noticed in our population was mucositis followed by hand-foot syndrome.Conclusion:Sunitinib is an option for the treatment of mRCC and shows a good PFS in Indian patients. Median OS and PFS in this study are similar to other reported studies despite the presence of poor risk factors in the patient population. The pitfall in this study is significant attrition due to poor compliance to treatment and follow-up, which is a major factor in the clinic thereby compromising outcomes.

show abstract

“…The median PFS was 10.2 months in our study, 11.4 months in Krishna et al .,[13] 9.3 months in Yuasa et al .,[13] 8.2 months in Kim et al .,[15] and 11.0 months in Motzer et al . [16]…”

Section: Discussionsupporting

confidence: 48%

Section: Discussioncontrasting

confidence: 46%

“…[13] and 90.2% in Kim et al . [15] The clinical efficacy rate (CR + PR + SD) was 86% in our study when it was 81% in Yuasa et al .…”

Section: Discussionmentioning

confidence: 99%

“…[15] The clinical efficacy rate (CR + PR + SD) was 86% in our study when it was 81% in Yuasa et al . [13] and 76% in Krishna et al . [13]…”

Section: Discussionmentioning

confidence: 99%

“…The median OS in our patients was 28.2 months when compared to 22.6 months in Krishna et al .,[14] 32.2 months in Yuasa et al . [13] and 23.1 months in Kim et al . [15]…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations